Phase III Study of Continuous Intravenous PPMX-T003 for Treating Aggressive NK Cell Leukemia in Adults
Led by Hiroshima University Hospital · Updated on 2025-04-30
7
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase III dose-escalation study to assess the tolerability, safety, efficacy, and pharmacokinetics of PPMX-T003 in patients with aggressive NK-cell leukemia. This study aims to better understand how this investigational treatment works and its effects in this serious condition. The research is sponsored by Hiroshima University Hospital.
Participants will receive PPMX-T003, administered as a continuous intravenous infusion. The study includes multiple courses of treatment, with the first course lasting 7 days and further courses up to a maximum of 35 days. The trial does not include a placebo group and is open-label, meaning both researchers and participants know the treatment being given.
During the study, participants will be monitored for adverse events and dose-limiting toxicities, particularly in the first 7 days after initial administration. Efficacy will be evaluated through liver volume assessed by CT scans, liver function tests, survival duration at 6 months, and the ability to transition to chemotherapy. Blood samples will be taken to measure drug concentration and immune response. The entire participation duration includes these monitoring and assessment periods up to six months.
CONDITIONS
Brief Title
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Research Team
K
Kiyoshi Ando
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients diagnosed with aggressive NK-cell leukemia based on WHO 4th edition (2017) criteria
You will not qualify if you...
Patients eligible to receive chemotherapy as treatment for aggressive NK-cell leukemia
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 35 days
Participants receive repeated continuous intravenous administration of the drug PPMX-T003 to evaluate tolerability, safety, efficacy, and pharmacokinetics.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Phase 12 Study of DR-01 to Test Safety and Effectiveness in Adults with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase III Study of Continuous Intravenous PPMX-T003 for Treating Aggressive NK Cell Leukemia in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia.